Evaluating Anti-Sickling Therapies for Sickle Cell Disease: A Microfluidic Assay for Red Blood Cell-Mediated Microvascular Occlusion Under Hypoxia

Key Points

• The microfluidic assay evaluates anti-sickling therapies' effects on RBCs under hypoxia, revealing treatment impacts.
• Key evidence shows that therapies may enhance RBC deformability and reduce occlusion in microvascular systems.
• This study employs a microfluidic assay to assess RBC behavior in a controlled hypoxic environment for accurate analysis.
• These findings highlight the importance of innovative assays in developing effective treatments for sickle cell disease.